Reference
- Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017 Feb 10. pii: S0016-5085(17)30148-8. doi: 10.1053/j.gastro.2017.02.004. [Epub ahead of print]